Articles related to CLINICAL STUDY

Survey responses from 5,797 Fox Insight participants suggest sleep disturbances, autonomic dysfunction, and emotional changes preceded Parkinson’s disease diagnosis by more than a decade in a substantial proportion of respondents.

A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.

Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

Adjunctive cognitive behavioral therapy reduced depressive symptoms and ideation scores versus treatment as usual in a 93-patient feasibility trial of esketamine for major depression with suicidal ideation.

Two retina specialists debated whether LIGHTSITE III evidence supports photobiomodulation as treatment for intermediate dry AMD, weighing modest BCVA gains against natural visual acuity variability, study quality concerns, and FDA authorization status.

A phase 3 head-to-head RCT of 689 patients found intravitreal brolucizumab preserved visual acuity at 54 weeks while panretinal photocoagulation patients lost a mean of approximately 4 letters, though intraocular inflammation rates were higher with brolucizumab.